Protein tyrosine phosphatases (PTPs) in diabetes: causes and therapeutic opportunities

Arch Pharm Res. 2021 Mar;44(3):310-321. doi: 10.1007/s12272-021-01315-9. Epub 2021 Feb 15.

Abstract

Protein tyrosine phosphatases (PTPs) have an emerging paradigm for the development of antidiabetic drugs. Herein, we provide a comprehensive overview of the relevance of PTPs to type 2 diabetes (T2D) and the therapeutic opportunities thereof, while critically evaluating the potential challenges for PTP inhibitors to be next generation antidiabetics. This review briefly discusses the structure and function of PTPs. An account of importance and relevance of PTPs in various human diseases is presented with special attention to diabetes. The PTPs relevant to T2D have been targeted by small molecule inhibitors such as natural products and synthetic compounds as well as antisense nucleic acids. This review will give better understanding of the important concepts helpful in outlining the strategies for the development of new therapeutic agents with promising antidiabetic activities.

Keywords: Antidiabetic agents; Antisense; Natural product; PTP inhibitor; Type 2 diabetes.

Publication types

  • Review

MeSH terms

  • Animals
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / metabolism*
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Protein Tyrosine Phosphatases / antagonists & inhibitors
  • Protein Tyrosine Phosphatases / metabolism*

Substances

  • Enzyme Inhibitors
  • Hypoglycemic Agents
  • Protein Tyrosine Phosphatases